Cellectar biosciences, inc. (CLRB)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
COSTS AND EXPENSES:
Research and development

8,996

6,835

9,465

4,750

5,158

5,964

6,860

5,122

3,599

2,984

General and administrative

5,182

4,820

4,135

4,699

3,395

3,704

4,444

3,632

2,692

1,156

Impairment of goodwill

0

1,675

0

-

-

-

-

-

-

-

Restructuring costs

-

-

-

-

203

221

1,096

0

-

-

Merger costs

-

-

-

-

-

-

-

0

746

52

Total costs and expenses

14,178

13,330

13,600

9,449

8,757

9,890

12,401

8,754

7,037

4,193

LOSS FROM OPERATIONS

-14,178

-13,330

-13,600

-9,449

-8,757

-9,890

-12,401

-8,754

-7,037

-4,193

OTHER INCOME (EXPENSE):
Grant income

-

-

-

-

-

-

-

0

44

200

Loss on revaluation of derivative warrants

43

62

22

3,261

3,667

2,285

2,373

-33

-

-

Gain/(loss) on revaluation of derivative warrants

-

-

-

-

-

-

-

-

-12

-

Loss on issuance of derivative warrants

-

-

-

-

-404

0

-744

0

-

-

Interest income, net

42

29

16

7

-0

-446

-9

-8

-430

-566

Other income

-

-

-

-

-

-

-

0

0

-0

Total other income, net

85

91

38

3,269

3,262

1,838

1,619

-42

-397

-366

NET LOSS

-14,092

-13,239

-13,562

-6,180

-5,495

-8,052

-10,782

-8,796

-7,435

-4,560

DEEMED DIVIDEND ON PREFERRED STOCK

0

2,241

1,448

3,179

-

-

-

-

-

-

DEEMED DIVIDEND ON WARRANTS

-

-

-

-

-

-

-

-543

0

-

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

-14,092

-15,480

-15,011

-9,360

-

-

-

-9,340

-7,435

-

BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE

-1.84

-5.23

-10.70

-2.14

-7.03

-17.53

-3.86

-0.23

-0.31

-0.36

SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE

7,675

2,961

1,403

4,366

781

459

2,794

41,121

23,959

-

SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE

-

-

-

-

-

-

-

-

-

12,820